ABSTRACT
In spite of high mortality from COVID-19, in Mexico the number of confirmed cases and diagnostic tests per million population are lower than for other comparable countries, which leads to uncertainty about the actual extent of the pandemic. In Mexico City, healthcare workers represent an important fraction of individuals with SARS-CoV-2 infection. This work aims to estimate the frequency of antibodies to SARS-CoV-2 and identify associated factors in healthcare workers at a large hospital in Mexico City. We conducted a serological survey in a non-COVID national referral teaching hospital. We selected a representative sample of 300 individuals. Blood samples were collected and questionnaires were applied between August 10th and September 9th, 2020. ELISA results indicate a serological prevalence of SARS-CoV-2 infection of 13.0%. Working in the janitorial and security groups, having an educational level below a university degree, and living with a larger number of people, were also identified as sociodemographic factors that increase the risk of having SARS-CoV-2 infection. Thus, less favored socioeconomic groups are at significantly higher risk of experiencing SARS-CoV-2 infection. Even in healthcare workers there is still a majority of individuals that are seronegative, and thus the risk of continued epidemic waves and mortality remains high.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received non-financial support (a donation of serological tests) for the conduct of this study. No other funding from a third party was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics and Research Committees of the Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra"
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data referred to in the mansucript can be made available by contacting the corresponding author.
